Pharmacokinetics and Pharmacodynamics Practice Questions

Q: A drug with high plasma protein binding property has which of the following properties?

Lower volume of distribution. ***Lower volume of distribution*** - Drugs with high plasma protein binding are largely confined to the **vascular compartment** as they bind to proteins (e.g., albumin, alpha-1-acid glycoprotein), making them less available to distribute into tissues. - This confinement within the plasma compartment results in a **smaller apparent volume of distribution**. *Less drug interaction* - High plasma protein binding actually increases the potential for **drug-drug interactions** through displacement. - If a second drug displaces the first from its binding sites, it can increase the **free fraction** and potentially lead to toxicity. *Reduced renal clearance* - While highly protein-bound drugs are generally not easily filtered by the glomeruli, their primary route of elimination is often through **hepatic metabolism** or **active tubular secretion**, rather than reduced renal elimination. - Many highly protein-bound drugs still undergo significant renal excretion via **active secretion**, if they are substrates for active transporters. *Less tubular secretion* - Plasma protein binding does not inherently reduce tubular secretion; in some cases, the drug-protein complex can dissociate rapidly at the secretory sites, allowing for efficient secretion of the **free drug**. - In fact, many drugs that undergo significant tubular secretion are also highly protein-bound, as protein binding helps **maintain a concentration gradient** for and delivery of the drug to the secretion transporters.

Q: At pKa = pH, what is the relationship between the ionic and non-ionic forms of a drug?

Conc. of drug is 50% ionic and 50% non-ionic. ***Conc. of drug is 50% ionic and 50% non-ionic*** - At **pKa = pH**, the concentrations of the **ionized** and **unionized** forms of a drug are equal as per the **Henderson-Hasselbalch equation**. - This means that exactly **half** of the drug molecules are in their charged (ionic) state, and the other half are in their uncharged (non-ionic) state. *Absorption of drug is 50% ionic and 50% non-ionic* - The amount of drug that is absorbed is dependent on the **non-ionic concentration** available at the absorption site, but this option incorrectly states that the *absorption itself* is 50% ionic. - Absorption primarily occurs for the **non-ionic, lipophilic form** as it can more readily cross cell membranes. *Conc. of drug is 75% ionic and 25% non-ionic* - This ratio would occur when the **pH** is either 0.5 units above the pKa for a weak acid or 0.5 units below the pKa for a weak base. - For example, if **pH = pKa + 0.5** (for a weak acid), approximately 75% would be ionic. *Conc. of drug is 25% ionic and 75% non-ionic* - This ratio would occur when the **pH** is either 0.5 units below the pKa for a weak acid or 0.5 units above the pKa for a weak base. - For example, if **pH = pKa - 0.5** (for a weak acid), approximately 25% would be ionic.

Q: Variation in sensitivity of response to different doses of a drug in different individuals is obtained from?

Dose-response relationship. ***Dose-response relationship*** - The **dose-response relationship** (particularly the **graded dose-response curve**) describes how the magnitude of a drug's effect changes with different doses. - When plotted for different individuals or populations, these curves reveal **variation in sensitivity** through differences in potency (horizontal shift) and efficacy (maximum response). - This relationship helps characterize inter-individual variability in drug response and is the fundamental concept for understanding differential sensitivity. *Therapeutic index* - The **therapeutic index** is a measure of drug safety, representing the ratio between the toxic dose and the effective dose (TD50/ED50 or LD50/ED50). - It does not directly explain the variation in sensitivity to different doses among individuals, but rather provides information about the drug's overall safety margin. *Bioavailability* - **Bioavailability** refers to the fraction of an administered drug that reaches the systemic circulation unchanged. - While it influences the drug concentration at the site of action, it doesn't directly measure the variability in physiological response to that concentration among individuals. *Phase 1 clinical trials* - **Phase 1 clinical trials** are the first stage of testing a new drug in humans, primarily focusing on safety, dosage range, and pharmacokinetics in a small group of healthy volunteers. - While variability in response may be observed during these trials, they are not the *pharmacological concept* that describes this variation; rather, dose-response relationships are used to interpret findings from these trials.

Q: Which of the following drugs is NOT metabolized by acetylation?

Metoclopramide. ***Metoclopramide*** - **Metoclopramide** is eliminated primarily via renal excretion, with a smaller portion undergoing glucuronidation and sulfation, not acetylation. - Its metabolic pathway does not involve the enzyme **N-acetyltransferase**, which is responsible for acetylation. *Dapsone* - **Dapsone** undergoes significant **N-acetylation** by NAT2 (N-acetyltransferase 2), which is important for its metabolism and clearance. - Genetic variations in NAT2 can lead to individual differences in **dapsone acetylation rates**, affecting drug efficacy and toxicity. *Procainamide* - **Procainamide** is primarily metabolized by N-acetyltransferase 2 (NAT2) to **N-acetylprocainamide (NAPA)**, an active metabolite. - Differences in **acetylation phenotype** (slow vs. rapid acetylators) influence the metabolism of procainamide and the risk of drug-induced lupus. *INH* - **Isoniazid (INH)** is extensively metabolized in the liver, primarily by **N-acetylation** via the enzyme N-acetyltransferase 2 (NAT2). - The rate of INH acetylation varies significantly among individuals, classifying them as **slow or rapid acetylators**, which impacts drug toxicity and efficacy.

Q: Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -

12.5 gm. ***12.5 gm*** - The formula for loading dose (LD) is: LD = (Target Concentration × Volume of Distribution) / Bioavailability. - Given: Target Concentration = 5 g/L, Volume of Distribution = 500 mL = 0.5 L, Bioavailability = 20% = 0.2. - So, LD = (5 g/L × 0.5 L) / 0.2 = 2.5 g / 0.2 = **12.5 g**. *1 gm* - This value would be obtained if the target concentration was 2 g/L with 100% bioavailability, or if the calculation incorrectly handled the volume or bioavailability factor. - It does not account for the specified **bioavailability of 20%** or the given target concentration and volume of distribution. *5 gm* - This result would be obtained if the bioavailability was assumed to be 50% (LD = 2.5 g / 0.5 = 5 g), or if the volume of distribution was incorrectly used in the calculation. - This option does not correctly factor in the **20% bioavailability** of the administered drug. *25 gm* - This value would result from mistakes such as dividing by bioavailability of 10% instead of 20% (LD = 2.5 g / 0.1 = 25 g), or by multiplying bioavailability instead of dividing by it. - This answer significantly **overestimates** the required dose, which could lead to drug toxicity.

Q: Fastest receptor mediated action is through?

Intrinsic ion channels. ***Intrinsic ion channels*** - Receptors that are also **ion channels** (ligand-gated ion channels) allow direct and rapid ion flow across the membrane upon ligand binding, leading to immediate changes in membrane potential. - This direct mechanism bypasses complex intracellular signaling cascades, resulting in the **fastest cellular response** compared to other receptor types. *Cell surface receptors* - This is a broad category that includes **G protein-coupled receptors** and **receptor tyrosine kinases**, which typically involve more complex and slower signaling pathways. - While located on the cell surface, not all receptors in this category mediate action as quickly as intrinsic ion channels. *Receptor tyrosine kinases* - These receptors initiate signaling by **phosphorylating tyrosine residues** on target proteins, triggering a cascade of intracellular events that take time to manifest. - Their action involves **multiple phosphorylation steps** and protein interactions, making their response slower compared to direct ion channels. *Intracellular receptors* - These receptors, such as **steroid hormone receptors**, are located in the cytoplasm or nucleus and require their ligands to diffuse across the cell membrane. - The activated receptor then typically translocates to the nucleus to regulate gene transcription, a process that is much **slower** due to gene expression and protein synthesis.

Q: Which of the following statements about oral iron preparations is correct?

Different preparations have different bioavailability. ***Different preparations have different bioavailability*** - The **bioavailability** of oral iron preparations varies depending on the specific salt used, its formulation, and the presence of absorption enhancers or inhibitors. - This difference in absorption impacts the required dose and efficacy in treating **iron deficiency anemia**. *Most commonly used preparation is ferrous gluconate* - **Ferrous sulfate** is the most commonly prescribed and cost-effective oral iron preparation due to its high iron content and good bioavailability. - While ferrous gluconate is used, its iron content is lower than ferrous sulfate, making it less frequently the primary choice. *Ferrous fumarate is most efficient* - While **ferrous fumarate** has a high elemental iron content, its efficiency doesn't necessarily surpass that of ferrous sulfate or other preparations when considering factors like bioavailability and side effect profile. - **Ferrous sulfate** is often considered efficient due to its balance of elemental iron content, bioavailability, and cost-effectiveness. *Ferric preparations are more effective* - **Ferrous (Fe2+)** iron is generally better absorbed than **ferric (Fe3+)** iron, as ferric iron needs to be reduced to its ferrous form before absorption. - Unless specifically formulated for enhanced absorption (e.g., ferric maltol), ferric preparations are typically *less* effective for initial iron repletion.

Q: Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

ED50 of the drug corresponds to efficacy. ***ED50 of the drug corresponds to efficacy*** - **ED50** (median effective dose) is the dose at which 50% of individuals exhibit the specified effect; it quantifies **potency**, not efficacy. - **Efficacy** refers to the maximum effect a drug can produce, while potency refers to the amount of drug needed to produce an effect. *In a clinical setup, efficacy is more important than potency* - **Efficacy** determines the maximal therapeutic benefit a drug can achieve for a patient, making it crucial for clinical outcomes. - While **potency** influences the dose required, a highly potent drug that is not very efficacious may not be clinically useful. *Drugs that produce a similar pharmacological effect can have different levels of efficacy* - Two drugs might act on the same receptor but elicit different maximal responses, indicating varying **efficacy**. - For example, a **partial agonist** and **full agonist** interacting with the same receptor will have different efficacies. *In the log dose response curve, the height of the curve corresponds with efficacy* - The **maximal response** or plateau of the dose-response curve represents the **efficacy** of a drug. - A higher plateau on the curve indicates a drug with greater intrinsic activity achieving a larger effect.

Q: High volume of distribution is primarily determined by:

High lipid solubility. ***High lipid solubility***- Highly **lipid-soluble** drugs readily cross biological membranes and distribute extensively into tissues, including adipose tissue, CNS, and intracellular compartments, leading to a **high volume of distribution (Vd)** [1, 2].- This property allows the drug to move out of the bloodstream and into various body compartments, increasing the apparent volume in which the drug is dissolved [1].*High plasma protein binding*- **High plasma protein binding** generally **restricts** drug distribution to tissues because only the **unbound (free) fraction** can diffuse across capillary membranes into interstitial fluid and cells [1].- This typically leads to a **lower Vd**, as the drug is largely retained within the plasma compartment.*Elimination rate*- The **elimination rate** determines how quickly the drug is removed from the body, affecting the **duration of action** rather than the extent of distribution.- It influences drug concentration changes over time but does not directly determine the physical space (volume) into which the drug distributes.*Half-life of the drug*- The **half-life (t½)** is the time required for drug concentration to reduce by half, and it is **determined by** both Vd and clearance (t½ = 0.693 × Vd/CL).- Half-life is a **consequence** of Vd and clearance, not a primary determinant of how widely a drug distributes [3].

Question 1

A drug with high plasma protein binding property has which of the following properties?

Accepted Answer

Lower volume of distribution

Answer

Reduced renal clearance

Answer

Less drug interaction

Answer

Less tubular secretion

Question 2

At pKa = pH, what is the relationship between the ionic and non-ionic forms of a drug?

Accepted Answer

Conc. of drug is 50% ionic and 50% non-ionic

Answer

Absorption of drug is 50% ionic and 50% non-ionic

Answer

Conc. of drug is 25% ionic and 75% non-ionic

Answer

Conc. of drug is 75% ionic and 25% non-ionic

Question 3

Variation in sensitivity of response to different doses of a drug in different individuals is obtained from?

Accepted Answer

Dose-response relationship

Answer

Therapeutic index

Answer

Bioavailability

Answer

Phase 1 clinical trials

Question 4

Which of the following drugs is NOT metabolized by acetylation?

Accepted Answer

Metoclopramide

Answer

Dapsone

Answer

Procainamide

Answer

INH

Question 5

Volume of distribution of a drug is 500 ml and target concentration of drug in blood is 5 g/L. 20% of administered drug is reached to systemic circulation. What will be the loading dose of that drug -

Accepted Answer

12.5 gm

Answer

1 gm

Answer

5 gm

Answer

25 gm

Question 6

Fastest receptor mediated action is through?

Accepted Answer

Intrinsic ion channels

Answer

Intracellular receptors

Answer

Cell surface receptors

Answer

Receptor tyrosine kinases

Question 7

Which statement best describes first-order kinetics in pharmacokinetics?

Accepted Answer

Elimination of the drug is proportional to the serum concentration

Answer

Absorption of the drug is independent of the serum concentration

Answer

Absorption of the drug is proportional to the serum concentration

Answer

Elimination of the drug is independent of the serum concentration

Question 8

Which of the following statements about oral iron preparations is correct?

Accepted Answer

Different preparations have different bioavailability

Answer

Most commonly used preparation is ferrous gluconate

Answer

Ferrous fumarate is most efficient

Answer

Ferric preparations are more effective

Question 9

Regarding the concepts of efficacy and potency of a drug, which of the following statements is FALSE?

Accepted Answer

ED50 of the drug corresponds to efficacy

Answer

Drugs that produce a similar pharmacological effect can have different levels of efficacy

Answer

In a clinical setup, efficacy is more important than potency

Answer

In the log dose response curve, the height of the curve corresponds with efficacy

Question 10

High volume of distribution is primarily determined by:

Accepted Answer

High lipid solubility

Answer

High plasma protein binding

Answer

Elimination rate

Answer

Half-life of the drug

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?